Europe — EMA
Palonosetron Stada
Palonosetron, the active ingredient in Palonosetron Stada, is a 5-HT3 receptor antagonist presented as an intravenous solution for injection use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Stada, is a 5-HT3 receptor antagonist presented as an intravenous solution for injection use. It treats and helps prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Palonosetron used for?
Palonosetron is used primarily by the oncology and surgical fields to manage nausea and vomiting. It covers the following recognised indications: - Chemotherapy‑induced nausea and vomiting (CINV): reduces the incidence and severity of acute and delayed CINV. - Post‑operative post‑operative vomiting (PONV): lowers the risk of vomiting after surgical procedures. - Radiotherapy induced vomiting (RINV): helps mitigate vomiting from radiation treatment. - Ant
What are the side effects of Palonosetron?
Palonoset
